Teva Pharmaceutical Industries recently received FDA acceptance of its supplemental Biologics License Application to expand AJOVY®'s use for preventing migraines in pediatric patients ...

Teva Pharmaceuticals and Samsung Bioepis have announced the US launch of Epysqli (eculizumab-aagh), a biosimilar to the blockbuster biologic Soliris (eculizumab), following FDA approval for the ...

We came across a bullish thesis on Teva Pharmaceutical Industries Limited (TEVA) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on TEVA. Teva Pharmaceutical ...

Drugmakers agree to participate in second round of price negotiations All drug manufacturers, including Novo Nordisk and Teva Pharmaceuticals , whose medicines are part of the second round of ...

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...

PARSIPPANY, NJ, USA and INCHEON, Korea I April 07, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Samsung Bioepis Co., Ltd. today ...

PARSIPPANY, N.J. - Teva Pharmaceuticals, a prominent player in the pharmaceutical industry with annual revenue of $16.54 billion and a market capitalization of $15.86 billion, has announced that the U ...

PARSIPPANY, N.J. - Teva Pharmaceuticals, a prominent player in the pharmaceutical industry with annual revenue of $16.54 billion and a market capitalization of $15.86 billion, has announced that ...

Teva Pharmaceuticals (TEVA) and Samsung Bioepis (SSNLF) announced the availability of EPYSQLI in the U.S. EPYSQLI is a biosimilar to Soliris for the treatment of paroxysmal nocturnal ...

EPYSQLI® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized ...

Several other research analysts have also commented on TEVA. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Samsung Bioepis Co., Ltd. today announced the availability of EPYSQLI® (eculizumab-aagh ...